| Trial ID: | L0989 |
| Source ID: | NCT00175227
|
| Associated Drug: |
Intravenous Saline Hydration + Mannitol + Furosemide
|
| Title: |
Prevention of Contrast-Induced Nephropathy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Contrast-induced Nephropathy|Acute Renal Failure|Chronic Renal Failure
|
| Interventions: |
DRUG: intravenous saline hydration + mannitol + furosemide|DRUG: intravenous saline hydration
|
| Outcome Measures: |
Primary: Proportion of patients that develop contrast-induced nephropathy after cardiac angiography, Within 48 hours of angiogram | Secondary: Safety of the intervention based on transfer to ICU, need for dialysis, or death, During hospitalization episode|Adverse clinical events and measures of renal function, 6 weeks post-angiogram|Health related quality of life, 6 weeks post-angiogram|Subgroup analyses based on (a) diabetes; (b) amount of contrast; and (c) baseline creatinine, Within 48 hours of angiogram
|
| Sponsor/Collaborators: |
Sponsor: University of Alberta | Collaborators: Alberta Heritage Foundation for Medical Research
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
1996-05
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2011-05-10
|
| Locations: |
University of Alberta Hospitals, Edmonton, Alberta, T6G 2B7, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00175227
|
